

Day 1 - Friday, 9 April, 2010	
1400 – 1405	Opening address David COLLINGRIDGE (UK)
1405 – 1413	Welcome address by Chair of local organising committee Ary Harryanto REKSODIPUTRO (Indonesia), Soehartati GHONDOWIARDJO (Indonesia)
Opening Plenary: Bridging the Gap Moderator: David COLLINGRIDGE (UK)	
1415 – 1450	Bridging science and global cancer – The IAEA's initiatives Werner BURKART (Austria)
1450 – 1525	Informing patients of treatment cost and managing expectation Michael JEFFORD (Australia)
1525 – 1600	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention Jack CUZICK (UK)
1600 – 1615	Q&A
1615 – 1645	Tea Break Exhibition & Networking
Haemato-Oncology Moderator: LIM Soon Thye (Singapore)	
1645 – 1715	Role of low molecular heparin in preventing thrombosis in oncology KWONG Yok Lam (HK)
1715 – 1745	The management of Hodgkin lymphoma: a never ending exciting story Volker DIEHL (Germany)
1745 – 1800	Q&A
End of Day 1	

Day 2 - Saturday, 10 April, 2010						
Cancer of the Connective Tissue Moderator: TBA						
0900 – 0930	Latest developments in treating sarcoma Ian JUDSON (UK)					
0930 – 1000	Development of targeted therapies for paediatric osteosarcoma Richard GORLICK (USA)					
1000 – 1015	Q&A					
1015 – 1100	Teatime sponsored symposium 1			Teatime sponsored symposium 2		
1100 – 1130	Tea Break Exhibition & Networking					
	Gastrointestinal Cancer Suite	Genitourinary Cancer Suite	Thoracic Cancer Suite	Women's Health Suite	Supportive Oncology Suite	
	GI Symposium 1 GIST	GU Symposium 1 Bladder Cancer	TC Symposium 1 Therapeutic Targets and Individualized Treatment in NSCLC Moderator: Chih-Hsin James YANG (Taiwan)	WH Symposium 1 Breast Cancer Molecular Biology Moderator: KHOO Kei Siong (Singapore)	SP Symposium 1 Managing the Side-Effects of Curative Treatment	
1130 – 1200	Molecular Aspects of GIST Richard QUEK (Singapore)	Radiation-based strategies in bladder conserving treatment for muscle invasive bladder cancer James DENHAM (Australia)	Novel targeted agents for lung cancer in Japan Nobuyuki YAMAMOTO (Japan)	Hereditary breast cancer in Asia – Epidemiology and Management Implications YIP Cheng Har (Malaysia)	Management of haematologic consequences of treatment and infection LIM Soon Thye (Singapore)	

1200 – 1230	Updates in management of GIST Yoon-Koo KANG (South Korea)	Bladder Cancer – will adjuvant chemotherapy ever be proven effective? Are we comfortable with the role of neoadjuvant therapy? Alvin WONG (Singapore)	The future of individualized treatment for NSCLC YANG Pan-Chyr (Taiwan)	Determination of prognostic markers – quality control and standardization TAN Puay Hoon (Singapore)	Management of nausea & vomiting, mucositis, and neuropathy Alexandre CHAN (Singapore)
1230 – 1245	Q&A	Q&A	Q&A	Q&A	Q&A
1250 – 1355	Satellite Lunch Symposium 1 (sponsored by Pfizer) Maximizing patient outcomes with targeted agents in mRCC: Current and future strategies			Satellite Lunch Symposium 2	
	<b>GI Symposium 2 Gastric Cancer</b>	<b>GU Symposium 2 Prostate Cancer I</b>	<b>TC Symposium 2 Personalised Therapy for Advanced NSCLC</b> Moderator: Tony MOK (Hong Kong)	<b>WH Symposium 2 Breast Cancer Adjuvant Therapy</b> Moderator: YIP Cheng Har (Malaysia)	<b>SP Symposium 2 Managing Cancer Pain</b>
1400 – 1430	Optimal treatment for gastric cancer: Tailor made surgery Cornelis JH VAN DE VELDE (Netherlands)	Prostate Cancer – Is the Asian diet protective? KOH Woon-Puay (Singapore)	Selecting first-line regimen for advanced NSCLC in Asia LU Shun (China)	Sentinel node biopsy – significance of micrometastases and its management SHAO Zhi-Ming (China)	An international standardization of assessment and classification of cancer pain - A new system emerging? Stein KAASA (Norway)
1430 – 1500	Targeted therapy in Gastric Cancer CHOO Su Pin (Singapore)	When do I NOT do a radical prostatectomy for prostate cancer? Rainy UMBAS (Indonesia)	Selecting patients for maintenance treatment in Asia Chih-Hsin James YANG (Taiwan)	Choosing the right adjuvant hormonal therapy for earlier breast cancer in the age of genomics Aman BUZDAR (USA)	Pain assessment and mechanisms MR RAJAGOPAL (India)
1500 – 1530	Chemotherapy in Gastric Cancer Wasaburo KOIZUMI (Japan)	State-of-the-art radiotherapy for prostate cancer: primary treatment, post-prostatectomy, and locally advanced disease James DENHAM (Australia)	Selecting patients for antiangiogenesis treatment in Asia Tony MOK (Hong Kong)	Triple negative breast cancer – what is the optimal adjuvant therapy? KHOO Kei Siong (Singapore)	Opioid and non-opioid use in control of cancer pain Pongparadee CHAUDAKSEKTRIN (Thailand)
1530 – 1545	Q&A	Q&A	Q&A	Q&A	Q&A
1545 – 1630	Teatime sponsored symposium 3 (sponsored by Pfizer) Tailoring breast cancer treatments with hormonal therapies			Teatime sponsored symposium 4	
1630 – 1700	Tea Break Exhibition & Networking				
	Editor's Choice Award: Oral Presentations Moderators: David COLLINGRIDGE (UK), James DENHAM (Australia)				
1700 - 1707	Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (MBC) Gilberto LOPES (Singapore)				
1708 - 1715	Identification of predictive biomarkers present prior treatment and associated with the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutics (ASCI) treatment in both melanoma and lung cancer Tony MOK (Hong Kong)				
1716 - 1723	Systems-level comparison of genomic data revealed difference between the cardia and non cardia gastric cancer Jae Yong CHO (South Korea)				
1724 - 1731	An exploratory phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases Amparo MACIAS (Cuba)				
1732 - 1739	Genetic polymorphisms of CYP2D6 and the outcome of breast cancer treated with adjuvant tamoxifen Byeong-Woo PARK (South Korea)				
1740 - 1747	The impact of pre-operative axillary assessment by ultrasound guided fine needle aspiration in screen-detected breast cancer Mohammad OMAIR (Australia)				
1748 - 1755	Accelerated BEP for advanced germ cell tumours: an ongoing multi-centre phase I/II trial Peter GRIMISON (Australia)				
1756 - 1803	Analysis of Epstein-Barr virus infection and multiple DNA methylation in nasopharyngeal carcinoma: value for early diagnosis Susanna Hilda HUTAJULU (Indonesia)				
1804 - 1811	A prognostic model to identify patients with curatively resected pancreatic ductal adenocarcinoma who could benefit from adjuvant chemoradiation therapy Young Suk PARK (South Korea)				
1812 - 1819	Antibodies against Epstein-Barr virus and DNA viral quantification as early screening tools of nasopharyngeal carcinoma Arina Prihestri NUGRAHENI (Indonesia)				

The Lancet Oncology/Clinical Oncological Society of Australia Plenary Session Moderators: Bruce MANN (Australia), David COLLINGRIDGE (UK)					
0830 – 0835	Introduction Bruce MANN (Australia)				
0835 – 0845	Can we improve informed consent? An international randomised controlled trial of consultation skills training Phyllis BUTOW (Australia)				
0845 – 0850	Discussant: Tony MOK (Hong Kong)				
0850 – 0900	The prognostic importance of p16INK4A and HPV in patients with oropharyngeal cancer treated with concurrent chemoradiation on TROG 02.02 phase III trial. Danny RISCHIN (Australia)				
0900 – 0905	Discussant: TOH Chee Keong (Singapore)				
0905 – 0915	Interim analysis of the APML4 trial incorporating all-trans retinoic acid (ATRA), idarubicin, and intravenous arsenic trioxide (ATO) as initial therapy in acute promyelocytic leukaemia (APL): An Australasian Leukaemia and Lymphoma Group (ALLG) study. Harry ILAND (Australia)				
0915 – 0920	Discussant: KWONG Yok Lam (Hong Kong)				
0920 – 0930	GOFURTO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). David GOLDSTEIN (Australia)				
0930 – 0935	Discussant: TBA				
0935 – 0945	Early results of a randomised trial comparing surgery alone with surgery plus post-operative radiation therapy following resection of melanoma involving regional lymph nodes – results of the TROG 02.01/ANZMTG 01.02 Intergroup Trial. Bryan BURMEISTER (Australia)				
0945 – 0950	Discussant: TOH Chee Keong (Singapore)				
0950 – 1005	Q&A / Discussions				
1005 – 1015	Editor's Choice Award: Oral presentations prize giving ceremony				
1015 – 1100	Teatime sponsored symposium 5			Teatime sponsored symposium 6	
1100 – 1130	Tea Break Exhibition & Networking				
	Gastrointestinal Cancer Suite	Genitourinary Cancer Suite	Thoracic Cancer Suite	Women's Health Suite	Supportive Oncology Suite
	GI Symposium 3 Hepatocellular Carcinoma	GU Symposium 3 Prostate Cancer II	TC Symposium 3 Recent Advances in Lung Cancer Research Moderator: Chih-Hsin James YANG (Taiwan)	WH Symposium 3 Updates in the Treatment of Gynaecologic Cancers Moderator: Efren DOMINGO (Philippines)	SP Symposium 3 Transiting from Curative to Palliative: Clinical Decision Making
1130 – 1200	Targeted Therapy in HCC CHENG Ann-Lii (Taiwan)	Optimal treatment of hormone-sensitive prostate cancer: have we max'ed out? Michael CARDUCCI (USA)	EGFR mutation in never smoker: Impact of second-hand smoking CHO Byoung Chul (South Korea)	Updates on management of endometrial cancer Hextan NGAN (Hong Kong)	Clinical decision making in advanced cancer Ghauri AGGARWAL (Australia)
1200 – 1230	Picking the right patients for transplant vs resection CHEOW Peng Chung (Singapore)	Hormone-resistant prostate cancer: have we made any progress since docetaxel? Michael CARDUCCI (USA)	Novel targets and phase I/II agents in NSCLC LIN Chia-Chi (Taiwan)	Updates on chemotherapy treatment of ovarian cancer Sarikapan WILAILAK (Thailand)	Panel discussion: Communicating options & eliciting patient preferences Ghauri AGGARWAL (Australia), Cynthia GOH (Singapore), MR RAJAGOPAL (India)
1230 – 1245	Q&A	Q&A	Q&A	Q&A	Q&A
1250 – 1355	Satellite Lunch Symposium 3			Satellite Lunch Symposium 4	
	GI Symposium 4 Colorectal Cancer Moderator: Cornelis JH VAN DE VELDE (Netherlands)	GU Symposium 4 Renal Cell Carcinoma	TC Symposium 4 Recent Advances in the Treatment of Lung Cancer Moderator: CHO Byoung Chul (South Korea)	WH Symposium 4 Cervical Cancer Prevention Moderator: Sarikapan WILAILAK (Thailand)	SP Symposium 4 Transiting from Curative to Palliative: Talking about DNR

1400 – 1430	CRC – Differences between East and West WU Ming Shiang (Taiwan)	RCC and the Art of Prognostication YE Ding-Wei (China)	Recent improvement in the imaging of pulmonary tumours Jin HUR (South Korea)	Primary prevention: HPV vaccine and it's future TAY Sun Kuie (Singapore)	Principles of communication Cynthia GOH (Singapore)
1430 – 1500	Is (neo)adjuvant therapy necessary in T3 rectal cancer? A surgeon's view – KOH Poh Koon (Singapore) A medical oncologist's view – Ian CHAU (UK)	RCC – the Asian anti-angiogenic experience RHA Sun Young (South Korea)	Recent improvement in the radiotherapy of pulmonary tumours FU Xiao Long (China)	Secondary prevention: The role of HPV testing in Asia Pacific Region Efren DOMINGO (Philippines)	Issues surrounding DNR Ednin HAMZAH (Malaysia)
1500 – 1530	Systemic Treatment of CRC Ian CHAU (UK)	Systemic management of non-clear renal cell cancer TAY Miah Hiang (Singapore)	Novel EGFR-TKIs Pasi JANNE (USA)	Tertiary prevention: New trends in radiotherapy for cervical cancer Wui-Jin KOH (USA)	Panel discussion: Talking about DNR Stein KAASA (Norway), Ednin HAMZAH (Malaysia), Cynthia GOH (Singapore)
1530 – 1545	Q&A	Q&A	Q&A	Q&A	Q&A
1545 – 1615	Tea Break Exhibition & Networking				
	<b>Neuro-Oncology</b> <i>Moderator: TBA</i>			<b>Skin Cancer</b> <i>Moderator: TBA</i>	
1615 – 1645	Genetic basis of glioma and potential for personalised medicine Michael WELLER (Switzerland)			Molecular vulnerabilities of melanoma Rick KEFFORD (Australia)	
1645 – 1715	New treatment regimens in the pipeline: an overview of current trials in treatment of glioblastoma Wolfgang WICK (Germany)			Treatment of melanoma: state of the art Claus GARBE (Germany)	
1715 – 1730	Q&A			Q&A	